mortality, volumetry was used for the measurement. For the adjustment of body size differences, retroperitoneal hematoma volume was divided by the abdominal cavity volume, and the calculated ratio was used for the validation under appropriate statistical methods.
101 EVAR patients and 82 patients included in the analysis was 25.7% and 24.4%, respectively, without statistically significant difference. Calculated mean retroperitoneal hematoma volume ratio of survivors and nonsurvivors was 3.59% 6 2.46% and 7.63% 6 3.45%, respectively (P < .001). Univariate analysis of other preoperative demographic and anatomical data are reported in the Table, and factors that were statistically significant (P < .05) were Glasgow Aneurysm Score (GAS) >85, systolic blood pressure <90 mm Hg, loss of consciousness, and mean minimum right external iliac artery diameter. To compare the usefulness as a predictor of perioperative mortality, receiver operating characteristics curves were drawn for retroperitoneal hematoma volume ratio and GAS for patients with Fitzgerald classification >3 (Fig) , since mortality rate of patients with Fitzgerald classification <2 was low (2 of 21 [9.5%]). Area under curve for retroperitoneal hematoma volume ratio and GAS was 0.880 and 0.587, respectively, suggesting retroperitoneal hematoma volume ratio as a good predictor of perioperative mortality. Maximum value of Youden's index for retroperitoneal hematoma volume ratio indicating best cutoff value was 6.97% (sensitivity, 0.833; specificity, 0.860).
Conclusions: Our study suggests that retroperitoneal hematoma volume is a good predictor of perioperative mortality after EVAR for rAAA, especially in FC >3 group with best cutoff value of 6.97%.
Author Disclosures: T. Akiyoshi: Nothing to disclose; N. Fujimura: Cook Medical: contracted research, W. L. Gore and Associates: consulting fees (eg, advisory boards); M. Inoue: Nothing to disclose; N. Isogai: Nothing to disclose; H. Ogino: Nothing to disclose; S. Ono: Nothing to disclose; S. Shibutani: Nothing to disclose; H. Yashiro: Nothing to disclose.
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Incidence of Thoracic Aortic Pathology on Low-Dose Computed Tomography Scans Done for Lung Cancer Screening
Micah Girotti, Michael Shockley, Mark Eskandari, Eric Hart, Tadaki Tomita. Northwestern University, Chicago, Ill
Objectives: Currently there is no approved thoracic aortic aneurysm (TAA) screening protocol as exists for the abdominal aorta. However, as a result of the National Lung Screening Trial, the Centers for Medicare and Medicaid Services (CMS) recently began covering annual low-dose computed tomography (LDCT) scans in long-term smokers, a population also at risk for developing aortic aneurysms. We hypothesized that these lung cancer screening scans represent a novel method of identifying TAA.
Methods: We identified 300 consecutive patients undergoing LDCT for lung cancer screening between the years 2014 and 2015 at a single center. Patient records were reviewed, and demographics and comorbidities were recorded. Each CT scan was reviewed, and the dimensions of the thoracic aorta were measured in three locations: immediately distal to the left subclavian artery, the middescending thoracic aorta, and immediately proximal to the celiac artery. We defined aortic ectasia as having a thoracic aortic diameter measuring between 3.5 and 4.0 cm, and aneurysm as measuring >4.0 cm.
Results: In total, 300 patients (157 [52%] men) were examined. The mean age was 61.6 years (range 43-78). There were 298 (99.3%) with a smoking history, with 141 (47%) being active smokers at the time of their initial scan. Common comorbidities included hyperlipidemia in 113 (37%), hypertension in 100 (33.3%), and chronic obstructive pulmonary disease in 37 (12.3%). Four patients (1.3%) had a personal history of abdominal aortic aneurysm (AAA): two had been repaired previously and two did not yet meet criteria for repair. There were 11 patients (4%) with a family history of AAA. Of the patients undergoing lung cancer screening, 166 (55.3%) met CMS criteria for AAA screening duplex. Overall, 11 patients (4%) had thoracic aortic ectasia, and one patient had a small distal TAA measuring 4.01 cm. The mean diameter of the aorta at the left subclavian artery in the population was 2.80 cm, 2.65 cm in the midthorax, and 2.59 cm at the celiac artery.
Conclusions: LDCT for lung cancer examines a population similar to that at risk for aortic aneurysm, with over half of the population in this sample meeting CMS criteria for AAA duplex screening. The thoracic aorta can be measured with acceptable accuracy on these scans. Overall, there is a low incidence of TAA in this population. Larger studies will need to be done to determine the impact of these scans on the diagnosis of thoracic aortic pathology.
Author Disclosures: M. Eskandari: Nothing to disclose; M. Girotti: Nothing to disclose; E. Hart: Nothing to disclose; M. Shockley: Nothing to disclose; T. Tomita: Nothing to disclose. Methods: A single-center study, approved by the Institutional Review Board, was retrospectively conducted on a prospectively compiled, 
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